Sabby Management LLC Takes $433,000 Position in Biodexa Pharmaceuticals PLC Unsponsored ADR $BDRX

Sabby Management LLC bought a new stake in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals makes up 0.6% of Sabby Management LLC’s holdings, making the stock its 10th biggest position. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals at the end of the most recent quarter.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Wall Street Zen cut shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, March 30th. Weiss Ratings lowered shares of Biodexa Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research report on Wednesday, June 3rd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Down 2.9%

NASDAQ BDRX opened at $2.98 on Wednesday. Biodexa Pharmaceuticals PLC Unsponsored ADR has a 1 year low of $2.86 and a 1 year high of $66.50. The business’s fifty day moving average is $3.46 and its two-hundred day moving average is $8.42.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last released its quarterly earnings data on Friday, March 27th. The company reported $3.52 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $3.53.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.